We are live on ! Find out more

Qiagen

QGEN

Market cap $10.4B

50.22 USD

-0.12

0.24%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

50.17

-0.05

0.1%

1 day

-0.24%

5 days

-0.4%

1 month

14.76%

3 months

21.16%

6 months

45.23%

Year to date

11.13%

1 year

8.4%

5 years

-14.91%

10 years

87.04%

About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between life sciences and molecular diagnostics applications. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).

Employees: 5,500

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 24.1%

Neutral 69%

Negative 6.9%

Zacks Investment Research

Do Options Traders Know Something About Qiagen Stock We Don't?

Investors need to pay close attention to QGEN stock based on the movements in the options market lately.

Do Options Traders Know Something About Qiagen Stock We Don't?

Zacks Investment Research

Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ultralife Corporation (Nasdaq – ULBI), QIAGEN N.V. (NYSE – QGEN), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)

BALA CYNWYD, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ultralife Corporation (Nasdaq – ULBI), QIAGEN N.V. (NYSE – QGEN), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: QIAGEN N.V. (NYSE – QGEN), Varonis Systems, Inc. (Nasdaq – VRNS), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)

BALA CYNWYD, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: QIAGEN N.V. (NYSE – QGEN), Varonis Systems, Inc. (Nasdaq – VRNS), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)

This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEN N.V. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of QIAGEN N.V. (NYSE: QGEN) to the EQT XI fund for €46.50 in cash per share.Halper Sadeh encourages QIAGEN shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether QIAGEN and its board of directors violated the federal secu.

QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEN N.V. is Obtaining a Fair Price for its Shareholders

QIAGEN reports preliminary Q3 2026 results

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates (CER). Adjusted diluted earnings per share (EPS) were $0.65, also $0.65 CER. QIAGEN plans to report full Q3 2026 results on Wednesday, November 4, 2026, at approximately 22:05 Frankfurt time / 16:05 New York time. Given the announced transaction wit.

QIAGEN reports preliminary Q3 2026 results

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer

VENLO, Netherlands & AMSTERDAM--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) and the EQT XI fund (“EQT Private Equity”) today announced an agreement under which Crown NL Bidco B.V. (the “Bidder”) announced its decision to make an all-cash voluntary public takeover offer for the acquisition of all outstanding QIAGEN shares at €46.50 per share (the “Takeover Offer”). The Bidder is a holding company indirectly controlled by EQT XI fund with f.

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer

EQT in advanced talks to buy testing firm Qiagen, Bloomberg News reports

European molecular testing company Qiagen is in advanced talks to be acquired by Swedish buyout ‌firm EQT, Bloomberg News reported on Tuesday, citing people familiar with the matter.

EQT in advanced talks to buy testing firm Qiagen, Bloomberg News reports

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from October 13-16 as a persistent disease burden and growing pressures on global health funding put renewed focus on tuberculosis prevention, screening and care. An estimated 10.7 million people worldwide developed tuberculosis in 2024 and nearly 1.2 million died from the d.

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

See News Rankings

Price charts implemented using Lightweight Charts™